Brief: AB Science Receives New Authorisations For masitinib Study
14/09/2021 17:31
Sept 14 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE ANNOUNCED THAT IT HAS RECEIVED NEW
AUTHORIZATIONS TO
RESUME PATIENT ENROLLMENT IN ITS PHASE 3 STUDIES OF MASITINIB
Source text for Eikon: ID:nGNX7tB5lb
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease